摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(3-phenylpropyl)piperazine dihydrochloride salt

中文名称
——
中文别名
——
英文名称
N-(3-phenylpropyl)piperazine dihydrochloride salt
英文别名
1-(3-phenylpropyl)-piperazine dihydrochloride;4-(3-phenylpropyl)piperazine dihydrochloride;1-(3-Phenylpropyl)piperazin-4-ium;chloride
N-(3-phenylpropyl)piperazine dihydrochloride salt化学式
CAS
——
化学式
C13H20N2*2ClH
mdl
——
分子量
277.237
InChiKey
CSEXKCDPFLQHQP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.95
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    15.3
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    N-(3-phenylpropyl)piperazine dihydrochloride salt 、 2-[bis(4-fluorophenyl)methoxy]ethyl iodide 在 sodium carbonate 作用下, 以 丁酮 为溶剂, 反应 24.0h, 生成 伐诺司林
    参考文献:
    名称:
    Scale-Up Synthesis of the Dopamine Uptake Inhibitor GBR-12909
    摘要:
    1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR-12909) is a dopamine uptake inhibitor. The development of a robust process for the preparation of this compound in kilogram quantities is described. The primary aims of the development work were to eliminate chromatographic purifications, to minimize the use of environmentally unacceptable reagents, and to improve the overall yield of the three-step convergent process. These objectives were met, with significant improvements obtained in the key coupling reaction of N-(3-phenylpropyl)piperazine dihydrochloride salt with 1-[bis(4-fluorophenyl)methoxy]-2-chloroethane, which was previously low-yielding and lacking in reproducibility.
    DOI:
    10.1021/op020211j
  • 作为产物:
    描述:
    苯基丙基哌嗪盐酸 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以111.5 g的产率得到N-(3-phenylpropyl)piperazine dihydrochloride salt
    参考文献:
    名称:
    Scale-Up Synthesis of the Dopamine Uptake Inhibitor GBR-12909
    摘要:
    1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR-12909) is a dopamine uptake inhibitor. The development of a robust process for the preparation of this compound in kilogram quantities is described. The primary aims of the development work were to eliminate chromatographic purifications, to minimize the use of environmentally unacceptable reagents, and to improve the overall yield of the three-step convergent process. These objectives were met, with significant improvements obtained in the key coupling reaction of N-(3-phenylpropyl)piperazine dihydrochloride salt with 1-[bis(4-fluorophenyl)methoxy]-2-chloroethane, which was previously low-yielding and lacking in reproducibility.
    DOI:
    10.1021/op020211j
点击查看最新优质反应信息

文献信息

  • ω-Quinazolinonylalkyl aryl ureas as reversible inhibitors of monoacylglycerol lipase
    作者:Florian M. Dato、Jörg-Martin Neudörfl、Michael Gütschow、Bernd Goldfuss、Markus Pietsch
    DOI:10.1016/j.bioorg.2019.103352
    日期:2020.1
    The serine hydrolase monoacylglycerol lipase (MAGL) is involved in a plethora of pathological conditions, in particular pain and inflammation, various types of cancer, metabolic, neurological and cardiovascular disorders, and is therefore a promising target for drug development. Although a large number of irreversible-acting MAGL inhibitors have been discovered over the past years, there are only few
    丝氨酸水解酶单酰基甘油脂肪酶(MAGL)涉及多种病理状况,特别是疼痛和炎症,各种类型的癌症,代谢,神经和心血管疾病,因此是药物开发的有希望的靶标。尽管在过去几年中发现了许多不可逆作用的MAGL抑制剂,但到目前为止,只有很少的已知化合物可逆地抑制酶。因此,在显示出可逆的抑制行为的新型化学实体上投入了大量的精力,认为这种化学实体引起较少的不良副作用。为了探索各种化学结构作为MAGL粘合剂,我们已经应用了一种虚拟筛选方法,即将小分子停靠在人类MAGL(hMAGL)的晶体结构中,并设想了45种选定化合物的库,然后将其合成。生化研究包括确定对hMAGL和两种相关水解酶的抑制能力,即人脂肪酸酰胺水解酶(hFAAH)和鼠类胆固醇酯酶(mCEase)。这些分析中最有希望的候选物,即三个带有3至5个亚甲基的烷基间隔基的ω-喹唑啉酮烷基烷基芳基脲,IC50值为20-41 µM,对hMAGL具有可逆的去污剂不敏
  • Scale-Up Synthesis of the Dopamine Uptake Inhibitor GBR-12909
    作者:Michael D. Ironside、Priyantha M. Sugathapala、Jerod Robertson、Mark C. P. Darey、Jianzhong Zhang
    DOI:10.1021/op020211j
    日期:2002.9.1
    1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR-12909) is a dopamine uptake inhibitor. The development of a robust process for the preparation of this compound in kilogram quantities is described. The primary aims of the development work were to eliminate chromatographic purifications, to minimize the use of environmentally unacceptable reagents, and to improve the overall yield of the three-step convergent process. These objectives were met, with significant improvements obtained in the key coupling reaction of N-(3-phenylpropyl)piperazine dihydrochloride salt with 1-[bis(4-fluorophenyl)methoxy]-2-chloroethane, which was previously low-yielding and lacking in reproducibility.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐